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The scarcity of kidneys for transplantation results in a highmortality
rate for waitlisted patients [1]. In comparison with long-term dialysis,
kidney transplantation results in better patient survival [2]. Unfortu-
nately, a lot of allografts are discarded because of an increased risk of
transmission of infection, such as the hepatitis C virus (HCV) [3].
Nearly 65% of the kidneys of HCV positive donorswere discarded be-
tween 2005-2014 [1], since HCV is associatedwith hepatic and extrahe-
patic complications. The virus has deleterious consequences in
recipients of a kidney transplant, resulting in reduced patient and
graft survival [4]. Due to high transmission rates, the viral transmission
could result in a chronic hepatitis C infection, with liver diseases such as
cirrhosis and even hepatocellular carcinoma as a consequence. There-
fore, transplanting kidneys from infective donors into uninfected recip-
ients could be considered unethical.octor Molewaterplein 40, 3015
et), k.m.van_dijk@lumc.nl
van den Hoogen).
. This is an open access article under
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antation Reviews, https://doiIn the past, antiviral therapywas based on the use of PEG-interferon-a
in combinationwith ribavirin. This treatment resulted in a sustained viro-
logic response in less than 50% of the patients [5]. In contrast, recently de-
veloped drugs called direct acting antivirals (DAA) have shown high rates
of sustained virologic response in HCV infected patients [6]. Moreover,
DAA cause fewer adverse effects and result in shorter treatment duration
[7]. Data on the prognosis of these patients remain controversial.
Several studies have analysed the outcomes of transplanting kidneys
from HCV positive donors, yet the results are inconsistent. Conse-
quently, the expected clinical course of transplanting these kidneys,
especially into an HCV negative recipient, remains uncertain.
The aim of this systemic review is to examine the consequences and
possibilities of transplanting kidneys from HCV positive donors to HCV
negative recipients in comparison with transplanting kidneys from
HCV negative donors.2. Method
2.1. Search strategy
We selected eligible studies by searching the Pubmed electronic
database using the following terms: (“Hepatitis C”[Majr] ORthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
ogen, Newpossibilities on transplanting kidneys fromhepatitis C virus
.org/10.1016/j.trre.2020.100532
Table 1
Quality assessment tool
Criteria Yes/No
1 Was donor HCV infectiveness measured by viral load?
2 Was the study population clearly deﬁned?
3 Was there an adjustment for potential confounding
variables?
4 Were the patient exclusion criteria clearly stated?
5 Did the article compare a D+/R- group with a D-/R- group?
Figure 1. Flowchart
2 R.C. van Riet et al. / Transplantation Reviews xxx (2020) xxx“Hepacivirus”[Mesh] OR “Hepatitis C Antibodies”[Mesh]) AND (“Hepa-
titis C”[tiab] OR “HCV”[tiab]) AND (“Kidney”[tiab] OR “Kidneys”[tiab]
OR “Renal”[tiab]) AND (“Kidney Transplantation”[Majr] OR “Renal
Replacement Therapy”[Mesh]) AND (“Transplant”[tiab] OR
“Transplantation”[tiab]) AND (“Recipient”[tiab] OR “Recipients”[tiab]
OR “Donor”[tiab] OR “Donors”[tiab]) AND (“Graft survival”[Mesh] OR
“Survival Rate”[Mesh] OR “Viral Load”[Mesh]).We restricted our search
to articles published between January 1st 2000 and November 7th 2019.
2.2. Study selection
One of the authors, KD, initially examined the titles and abstracts of
the search results. Articles that did not focus on the hepatitis C virus in
the context of kidney transplantation were excluded. Subsequently,
both authors assessed the full text of the remaining articles for eligibil-
ity.We discussed any disagreements and came to a consensus. Based on
the residual articles, we put together the following exclusion criteria:
• Articles not written in English
• Case reports
• Articles that discussed multi-organ transplantations
• Articles that did not focus on HCV+ donors transplanting kidneys to
HCV- recipients
2.3. Data extraction
Our primary outcome measurement was the difference in patient
survival betweenHCVpositive donors transplanting toHCVnegative re-
cipients (D+/R-) and a control group of HCV negative donors
transplanting to HCV negative recipients (D-/R-). Patient survival is de-
ﬁned as the time between the date of transplant and death, themost re-
cent follow-up date or the end of the study period.
As secondary outcome measurements we looked at graft survival,
HCV transmission and the cause of death of the recipients. Graft failure
is deﬁned as return to dialysis after transplantation or deathwith a func-
tioning graft. Apart from the parameters mentioned above, we ex-
tracted data on mean follow-up time, testing of donor infectiveness
and mean recipient age. We only used data on cause of death if the
cause was reported in more than one of the studies, to make an ade-
quate comparison between the selected articles. Testing of infectiveness
of the donor using viral load was of relevance because serology cannot
discriminate a chronic infection from a cleared infection. The same ap-
plies for detecting HCV transmission in the recipients. When available,
we also focused on the patient survival of the D+/R- group compared
with waitlisted controls.
2.4. Quality assessment
We independently assessed the quality of the selected articles.
Table 1 presents the criteria we composed to evaluate the articles. We
used the Newcastle- Ottawa Quality Assessment Scale [8] as a guideline
to set up the criteria. We excluded articles with a score of 3 “No’s” or
more.
To prevent confounders, the baseline characteristics of the study
population must be clearly deﬁned and the study population must be
speciﬁed by exclusion criteria. To verify donors were truly infective at
time of donation, RNA viral load has to be measured and has to be
found positive. Potential confounders such as age and comorbidities re-
quired proper adjustment for reliable results. Furthermore, the article
must compare an HCV positive donor transplanting to an HCV negative
recipient (D+/R-), with anHCV negative donor transplanting to anHCV
negative recipient (D-/R-) to come to a well-considered conclusion.
We used the PRISMA checklist as a guidance for the structure of this
systemic review [9].Please cite this article as: R.C. van Riet, K.M. vanDijk andM.W.F. van denHo
positive donors: a Systematic Revi..., Transplantation Reviews, https://doi3. Results
3.1. Study selection
The outcome of the study selection is shown in Figure 1. Our search
terms resulted in a set of 158 articles of which 12 remained after selec-
tion (see Figure 1). We found three other articles [10–12] that also met
our inclusion criteria. These three articles do not haveMeSH terms since
they are published very recently and for this reason they could not beogen, Newpossibilities on transplanting kidneys fromhepatitis C virus
.org/10.1016/j.trre.2020.100532
Table 2
Quality assessment of the included studies
Study 1 2 3 4 5
Gupta, G., et al. Yes Yes No Yes No
Molnar, M.Z., et al. Yes Yes No Yes No
Friebus-Kardash, J., et al. Yes Yes No Yes Yes
La Hoz, R.M., et al. Yes Yes No Yes Yes
Reese, P.P., et al. Yes Yes No Yes No
Trotter, P.B., et al. No No No No Yes
Durand, C.M., et al. Yes Yes No Yes No
Gupta, G., et al. No Yes Yes Yes Yes
Goldberg, D.S., et al. Yes Yes No Yes No
Morales, J.M., et al. No No No No Yes
Singh, N., et al. No Yes Yes No Yes
Flohr, T.R., et al. Yes⁎ Yes No No Yes
Abbott, K.C., et al. No Yes Yes Yes Yes
Bucci, J.R., et al. No Yes Yes Yes Yes
Rozental, R., et al. No No No No No
⁎ 3 out of 13 donors tested by NAT
3R.C. van Riet et al. / Transplantation Reviews xxx (2020) xxxfound through our search terms. Therefore, we additionally included
these articles in our study selection, leading to 15 articles in total.3.2. Study characteristics and quality assessment
The quality assessment is shown in Table 2. As a result of the quality
assessment, we excluded three more articles: Trotter, P.B., et al. [13],
Morales, J.M., et al. [14] and Rozental, R., et al. [15]. These studies had
three or more “No’s”.
In sum, we included twelve articles in this systematic review. The
study characteristics of these articles are shown in Table 3.Table 3
Study Characteristics
Authors Year of publication Number of patients included
Gupta, G., et al. 2019 D+/R-: n=50
Molnar, M.Z., et al. 2019 D+/R-: n=53
Friebus-Kardash, J., et al. 2019 D+/R-: n=7
La Hoz, R.M., et al. 2019 D+/R-: n=196⁎
D+/R-: n=352⁎⁎
D-/R-: n=36934
Reese, P.P., et al. 2019 D+/R-: n=20
Durand, C.M., et al. 2018 D+/R-: n=10
Gupta, G., et al. 2017 D-/R-: n= 2105 D+/R-: n=421
Goldberg, D.S., et al. 2017 D+/R-: n=10
Singh, N., et al. 2012 D-/R-: n=1897 D+/R-: n=118
Flohr, T.R., et al. 2011 D-/R-: n=90 D+/R-: n=13
Abbott, K.C., et al. 2003 D-/R-: n=34151 D+/R-: n=280
Bucci, J.R., et al. 2002 D-/R-: n=16337 D+/R-: n=165
ND = not determined
⁎ Donor infectiveness tested by NAT
⁎⁎ Donor infectiveness tested by serology
⁎⁎⁎ Subtype unknown
Please cite this article as: R.C. van Riet, K.M. vanDijk andM.W.F. van denHo
positive donors: a Systematic Revi..., Transplantation Reviews, https://doiAs shown in Table 4, six studies only used NAT to test donor
infectiveness [10,12,16–19]. Together, these studies resulted in a total
study population of 150 recipients. These 150 recipients had a mean
viral transmission rate of 67.3% and a sustained virologic response of
100%. Five of these studies [10,16–19] resulted in a patient survival of
100%. In the study of Gupta, G., et al. [12] one patient died of pneumonia,
leading to a patient survival of 98%. La Hoz, R.M., et al [11] reported a 12-
month patient survival for the D+/R- group of 100%, compared to 97.2%
in the D-/R- group (p=0.23).
Five studies reported a lower survival rate of the patients in the D+/
R- group in comparison with the D-/R- group. Gupta, G., et al. [3] com-
pared the D+/R- group to matched waitlisted controls as well, and re-
ported a signiﬁcant better survival for the D+/R- patients. 3-year
survival was reported as 84% for the D+/R- group versus 56% for
matchedwaitlisted controls (pb0.001). 5-year survivalwas 68%, respec-
tively 43% (pb0.001).
Nine articles gave insight into the number of graft survival. Two ar-
ticles reported signiﬁcantly worse graft survival in the D+/R- group
[3,20]. One article reported a better graft survival for the D+/R- group,
yet this result was not signiﬁcant [11].
Gupta, G., et al. [3] and Flohr, T.R., et al. [21] reported a transmission
rate of 49% respectively 62%. However, four studies reported that the
donor HCV was transmitted to all recipients by transplantation
[10,16,18,19]. Durand, C.M., et al. [17] and Gupta, G., et al. [12] reported
a HCV transmission rate of respectively 50% and 12% after the recipients
received pre-transplant prophylaxis with DAAs.
The three most commonly used types of DAA combinations were
elbasvir-grazoprevir (EBR-GZR), sofosbuvir-velpatasvir (SOF-VEL),
sofosbuvir-ledipasvir (SOF-LDV). One study used glecaprevir-
pibrentasvir (GLE-PIB) as DAA treatment [16]. Two studies used ribavi-
rin (RBV) as additional treatment [10,18].Follow-up time (yr) Testing of donor infectiveness Donor HCV genotype
0.23 NAT 1a (n=19)
2a (n=1)
2b (n=1)
3 (n=6)
ND (n=23)
Median 0.83 (0.79-0.98) NAT 1a: n=34
1b: n=1
2: n=3
3: n=15
1 NAT 1 (n=4)
1b (n=1)
3a (n=2)
3 NAT⁎
(n=196) Serology⁎⁎ (n=352)
ND
1 NAT 1 (n=20)
Median 0.23 (IQR
unknown)
NAT (n=9)
Undetectable HCV RNA (n=1)
1a: n=3
1a-3: n=1
2: n=1
3: n=1 ND: n=4
Median 0.85
(0.38-8.00)
Serology ND
Median 0.5 (IQR
unknown)
NAT 1a: n=9 1⁎⁎⁎: n=1
Mean 6.02 ±
4.26 SD
Serology ND
Median 1.5
(0.78-6.28)
NAT (n= 3)
Unknown (n=10)
ND
Mean 2.77 ±
1.66 SD
Serology ND
Mean 1.85 ±
1.12 SD
Serology ND
ogen, Newpossibilities on transplanting kidneys fromhepatitis C virus
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Table 4
HCV transmission, survival rates and cause of death of the D+/R- group and D-/R- group
Authors Mean recipient
age (yr)
± SD
HCV
transmission to recipients
in D+/R- group
Treatment Graft survival Patient survival Cause of death
Gupta, G., et al. (2019) 60 12% detectable HCV RNA,
100% cured
SOF-VEL
EBR-GZR
96% 98% Pneumonia (n=1)
Molnar, M.Z. et al.
(2019)
52.6 ± 10.9 100%
detectable HCV RNA, 100%
cured
Triple therapy (100%)
DAA:
GLE-PIB (89%) SOF-VEL (9%)
SOF-LDV (2%)
100% 100% -
Friebus-KardashJ.,
et al (2019)
53 100% detectable HCV RNA,
100% cured
SOF-LDV (43%)
SOF-LDV+ RBV (14%)
SOF-VEL (43%)
Triple treatment Basiliximab
100% 100% -
La Hoz, R.M., et al.
(2019)
52.1 (13.5) ND Induction
None (9.4%)
IL2-RA (13.6%)
r-ARTG (56.9%)
Alemtuzumab (n=15.4%)
Other (n=4.7%)
12-mo:
D+/R-:98.4%
D-/R-: 94.2%
(p=0.17)
HR 0.85
[0.25-2.96]
12-mo:
D+/R-:100%
D-/R-:97.2 %
(p=0.23)
ND
Reese, P.P., et al.
(2019)
56.3 (6.7) 100% detectable HCV RNA,
100% cured EBR-GZR (n=17)
EBR-GZR + RBV (n=3)
100% 100% -
Durand, C.M.,
et al. (2018)
Median age 71.0 50%
detectable HCV RNA, 100%
cured
Triple therapy (100%)
DAA: EBR-GZR (100%)
SOF (additional) (20%)
100% 100% -
Gupta, G., et al.
(2017)
55.8 ±12.26 49% (n=62)
Seroconverted
MMF/azathioprine (83.3%)
TAC (93.3%)
Steroids (78.6%)
3-yr:
D-/R-: 78%
D+/R-: 66%
(pb0.001)
5-yr:
D-/R-: 65%
D+/R-: 44%
(pb0.001)
HR: 1.76
[1.1-2.05]
3-yr:
D-/R-: 87%
D+/R-: 76% (pb0.001)
5-yr:
D-/R-: 79%
D+/R-: 57%
(pb0.001)
HR: 2.06
[1.7-2.49]
Liver disease:
D+/R-: 1.6%
Infection:
D-R-: 16.2%
D+R-: 24.9%
(pb0.01)
Goldberg, D.S.,
et al.(2017)
Median age: 59.0 100%
detectable HCV RNA,
100% cured
Triple therapy (100%)
DAA: EBR-GZR (100%)
- 100% -
Singh, N., et al.
(2012)
- - Azathioprine (24.3%) or
mycophenolic acid (73.1%)
MMF (100%)
Before 1999: cyclosporine
(61.5%)
After 1999:
TAC (22.8%)
Prednisone (100%)
10-yr:
D-/R-: 48.3%
D+/R-: 16.2%
(pb0.01)
HR: 2.1
[1.6-2.6]
10-yr:
D-/R-: 64.8%
D+/R-: 22.6%
(pb0.01)
HR: 2.5
[1.9-3.2]
Liver failure
D-/R-: 1%
D+/R-: 4%
Infection
D-/R-: 18%
D+/R-: 16%
CVD
D-/R-: 22%
D+/R-: 24%
Flohr, T.R., et al.
(2012)
72.0 62% (n=8)
detectable HCV-RNA
TAC (100%)
MMF (69%)
Prednisone (100%)
- 1-yr:
D-/R-: 82.3%
D+/R-: 46.1%
(pb0.008)
Infection
D+/R-: 23%
Abbott,
K.C., et al.
(2003)
47.0 ±12.5 - Cyclosporine (67.8%)
TAC (42.5%)
Azathioprine (23.8%) MMF
(78.9%)
Steroids unknown
1-yr:
D-/R-: 93.6%
D+/R-: 93.6%
HR: 0.77
[0.25-2.42]
(p=0.66)
1-yr:
D-/R-: 88.2%
D+/R-: 74.6%
(pb0.01)
AHR: 2.30
[1.75-3.26] (p=0.025)
Liver
disease
D-/R-: 1.5%
D+/R-: 6.9%
CVD
D-/R-: 22.8%
D+/R-: 13.2%
Bucci, J.R., et al.
(2002)
48.13 ± 11.14 - Cyclosporine
(79.6%)
TAC (11.4%)
Azathioprine (43.1%) MMF
(46.4%)
- D-/R-:86.4%
D+/R-: 69.7% (pb0.01)
HR: 1.46
[1.04-2.05]
(p=0.028)
Liver
disease: D+: 6.6
D-: 0.5%
Infection
D+: 28%
D-: 32%
CVD:
D+: 56%
D-: 49%
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5R.C. van Riet et al. / Transplantation Reviews xxx (2020) xxxSeveral studies described cardiovascular disease (CVD) as the most
common cause of death for both the D-/R- as well as the D+/R-
group. Another frequently registered cause was infection. Death by
liver disease was more often reported in the D+/R- group than in the
D-/R- group. Flohr, T.R., et al. [21] reported one death directly caused
by HCV liver disease, speciﬁcally cholestatic hepatitis.
4. Discussion
4.1. Summary of evidence
This systematic review shows that, since the usage of DAA treat-
ment, kidney transplantations from HCV infected donors to uninfected
recipients could result in high graft survival and patient survival rates.
Patient survival is superior in the D+/R- group, compared to waitlisted
controls. Viral transmission ranged from 12% to 100%, depending on the
rate of testing viral load and pre-emptive treatment [10,12,16–19,21].
4.2. Limitations
Initially, we excluded threemore articles as a result of the quality as-
sessment. The remaining twelve articles did not meet all of the criteria.
However, every study had its individual strengths. Thus, due to the het-
erogeneity of the studies, we did not attach more importance to one
study over another.
Six out of the twelve remaining studies were retrospective observa-
tions. These studies depended on databases, which inherently contain
errors and shortcomings. Several studies reported missing data on
cause of death of the recipients, in some cases leading up to nearly
50% [22]. Additionally, granular data on pretransplant comorbidities of
the recipients were not present or not mentioned in the greater part
of the studies.
Moreover, we noticed intra-study variance as well as heterogeneity
between the studies in demographic characteristics. Bucci, J.R., et al.
[22], Singh, N., et al. [20] and Gupta, G., et al. [3] reported more recipi-
ents of the African American (AA) race in the D+/R- group. The AA
race is widely considered a risk for poorer patient and graft survival.
This might be explained by the fact that African Americans have a
lower rate of viral clearance and a higher rate of chronic hepatitis C,
when treated with PEG-interferon and ribavarin [3]. Other reported de-
mographic inequalities were a longer cold ischemic time and longer
pretransplant dialysis for theD+/R- group. On top of that, the recipients
of the D+/R- group were older and thus more fragile (e.g. recipients
aged N50 y have a risk of 67% increase in ﬁbrosis progression rate [21]).
The elderly were also an inter-study variance. Flohr, T.R., et al. [21]
speciﬁcally focussed on the elderly recipient population. Therefore, it
is quite difﬁcult to compare Flohr, T.R., et al. [21] to the other studies be-
cause of the heterogeneity of the study population. The same applies to
the race of the recipients, which varies in the different studies.
Additionally, the follow-up time differed between the studies. Five
studies had a follow-up time of less than one year [12,16–19]. Hence,
they could not report on the long-term outcomes of the transplantation.
Data on the outcomes of the trial of Goldberg, D.S., et al. [19] and
Durand, C.M., et al. [17] would have been interesting, because the recip-
ients completely cleared the virus. Although the study ofMolnar,M.Z. et
al. [16] did had a signiﬁcantly longer follow-up time compared to Gold-
berg, D.S., et al [16] and Durand, C.M., et al [10], the median follow-up
time was less than a year, speciﬁcally 302 days. Thus, the study does
give a better insight into the patient survival, but a longer follow-up
time is still required to demonstrate the long-term outcomes.
Furthermore, only Abbott, K.C., et al. [23] adjusted its results for co-
morbid conditions. Comorbidities can be an important confounder for
patient survival. It is remarkable that in this one study, the patient sur-
vival of the D+/R- group is better than in the other studies.
The retrospective data is mostly from an era in which HCV RNA test-
ing was not universally available. Five studies used antibody testing toPlease cite this article as: R.C. van Riet, K.M. vanDijk andM.W.F. van denHo
positive donors: a Systematic Revi..., Transplantation Reviews, https://doiexamine whether the donor was HCV positive. As stated, serology is
not precise to determine the infective state of the donor. Donors could
have cleared their HCV infection prior to the kidney transplantation.
Flohr, T.R., et al. [21] tested only three donors by viral load and La Hoz,
R.M., et al. [11] reported on 352 recipients who received a kidney from
a donor tested positive by serology. It is possible that not all donors
were infective at time of transplantation and therefore HCV transmis-
sion rates could be underestimated. Consequently, the risk of using
the allografts of those donors is equivalent to HCV negative donors.
Therefore the results of these ﬁve studies should be interpreted with
caution. On top of that, studies that used serologymost likely conducted
selection bias, because donors of whom they knewwere truly infective,
were possibly rejected as a donor.
Concerning transmission rates, Durand, C.M., et al. [17] and Gupta,
G., et al. [12] used DAA prophylaxis, which could explain the lower
HCV transmission rates. The virus could have been cleared before the
ﬁrst time of virus RNA measurement of the recipients in these studies.
The direct acting antivirals are a breakthrough in the treatment of
HCV. A study of Pecoraro V., et al. [24] showed that when compared to
placebo, treatment with DAAs plus PEG-interferon-a in combination
with ribavirin increase the 12 week SVR from 54% to 78% in naïve HCV
patients.With DAA treatment, a higher SVR can be achieved, potentially
leading to clinical beneﬁts. As can be seen in the included studies, com-
pletion of antiviral therapy resulted in a SVR of 100%.
A recently published trial of Franco, A. et al. [25] showed successful
transplantations in eleven patients. However, this study did not report
on viral transmission and it is therefore unclear whether the recipients
were infected in the ﬁrst place. Since only one donor was evidently NAT
positive, merely two recipients have received a kidney from an infective
donor. This sample size does not contribute to the data shown by the in-
cluded studies.
Although the included studies did not focus on theﬁnancial aspect of
DAA treatment, it should be noted that these drugs are expensive [26].
Currently, it is uncertain who will bear these costs in non-research set-
tings. It should be questioned whether the usage of this viral regimen is
ethically justiﬁed considering the cost-beneﬁt ratio.
There is still no clear evidence on why the patient survival of the D
+/R- group is relatively worse. For HCV negative recipients the dona-
tion causes a primary infection, which is likely to be worse in compari-
son with a donation to HCV positive recipients. Research has shown
intrahepatic complications in HCV negative recipients, such as ﬁbrosing
cholestatic hepatitis, as well as extrahepatic complications, such as high
rates of newonset diabetes after transplantation [27]. On top of that, im-
munosuppressive therapy could facilitate viral replication [28]. How-
ever, an absolute explanation is not found yet [29].
Furthermore, six studies [10,12,16–19] showed a different outcome
due to the DAA treatment. Most of these studies only included twenty
patients or less, which is whywe suggest that these studies are to be re-
peated in the future, with inclusion of more patients and a control
group.
Other disciplines are looking at the use of DAA treatment as well. A
recent published trial involving transplantation of hearts and lungs
from HCV positive donors into patients without HCV infection, resulted
in a prevention of the establishment of HCV infection with DAA treat-
ment for 4 weeks [30].
In the era the other studies were conducted, DAA treatment was not
available and antiviral therapywas based on the use of PEG-interferon-a
in combinationwith ribavirin.With this treatment, a sustained virologic
response could not be accomplished in 50% of the patients [5]. Conse-
quently, the results of the other six studies could have been different if
an antiviral regimenwould have been available at that time. A complete
clearance of the hepatitis C virus can diminish the several risks reported
in the other studies. Further monitoring of the patients who cleared the
virus after transplantation is required to analyse the long-term out-
comes.Moreover, the timing and especially the length of DAA treatment
and the moment of initiation requires more studies.ogen, Newpossibilities on transplanting kidneys fromhepatitis C virus
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part of the HCV positive kidney donors from the United States are
young, healthy and died of drug overdose [31]. It should be questioned
if the positive effect on patient and graft survival (as shown by the arti-
cle of La Hoz, R.M., et al. [11]) also applies to recipients from other parts
of the world, since most other countries might not have comparably
healthy and young hepatitis C infective donors. Furthermore, all current
infective hepatitis C donors are DAA-treatment naive, and therefore SVR
in the recipient is expected to be high. If the donor has shown resistance
to DAA (although very uncommon), this might severely hamper effec-
tive treatment in the recipient. In these speciﬁc cases, we advise against
use of these donor organs.
A recent published position statement demonstrates the current lit-
erature on this topic [27]. The authors emphasize the possibilities to ac-
complish a SVR when recipients are treated with pangenotypic direct
acting antivirals. They recommend further implementation of D+/R-
kidney transplantations, with pre-emptive treatment of DAA, which
could ultimately lead to a cost-effective treatment. All in all, the report
demonstrates data in line with this systematic review.
5. Conclusion
Despite the high likelihood of viral transmission, acceptance of a kid-
ney from an HCV infected donor can result in superior patient survival
compared to remaining on the waiting list. In this era, a sustained viro-
logic response can be achievedwith DAA treatment, possibly improving
long-term outcomes.
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